NeOnc Technologies (NTHI) vs Zhengye Biotechnology (ZYBT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Zhengye Biotechnology (ZYBT) has outperformed NeOnc Technologies (NTHI) over the past year, losing 36.4% versus a loss of 76.8%. Zhengye Biotechnology is the larger company by market cap ($82.0 million vs $80.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NTHI | ZYBT |
|---|---|---|
| Share price | $2.78 | $1.73 |
| Market cap | $80.08M | $81.99M |
| 1-day change | +9.88% | +50.45% |
| YTD return | -66.38% | +50.43% |
| 1-year return | -76.79% | -36.40% |
| EPS (TTM) | $-2.13 | $-0.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.09 | $8.01 |
| 52-week low | $2.50 | $0.616 |
| Distance from 52-week high | -77.01% | -78.40% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +511.51% | — |
| Average volume | 195.17K | 5.10M |
| Shares outstanding | 28.81M | 47.39M |
| Employees | 5 | 269 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZYBT has outperformed NTHI by 40.4 percentage points over the past year.
About NeOnc Technologies
NTHI stock →NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
About Zhengye Biotechnology
ZYBT stock →Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in the People's Republic of China. The company offers vaccines for swine, cattle, goats, sheep, poultry, and dogs, as well as monovalent vaccine, polyvalent vaccine, combined vaccine, and combined and polyvalent vaccine.
Health Care · Biotechnology: Pharmaceutical Preparations · 269 employees
NTHI vs ZYBT FAQ
Which is bigger, NeOnc Technologies or Zhengye Biotechnology?
Zhengye Biotechnology (ZYBT) is larger, with a market capitalization of $81.99M compared with $80.08M for NeOnc Technologies (NTHI).
Which stock has performed better over the past year, NTHI or ZYBT?
ZYBT returned -36.40% over the past 12 months, compared with -76.79% for NTHI (price return, excluding dividends). Past performance does not predict future results.
Are NeOnc Technologies and Zhengye Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.